LONDON (Alliance News) - C4X Discovery Holdings PLC and e-Therapeutics PLC on Thursday said that, through their collaboration, they discovered additional novel biological pathways for the treatment of Parkinson's disease.
Both companies believe that further work could "transform the treatment landscape" for patients suffering from the disease.
Parkinson's is a progressive neurological disease affecting up to 10 million people worldwide.
Craig Fox, chief scientific officer at C4XD, said: "This combination [between the two companies] has identified additional novel biological pathways for the treatment of Parkinson's disease and we look forward to moving these findings forward to initiate new drug discovery programmes."
The two drug discovery companies announced a cooperation aiming to identify novel intervention strategies for the potential treatment of Parkinson's back in May.
e-Therapeutics shares were trading up 4.1% at 6.90 pence, while C4X shares were up 2.8% at 74.50p.
